Frontiers in endocrinologySep 5, 2025

A decade of progress in type 2 diabetes and heart disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

This notice records a correction to a review on type 2 diabetes, cardiovascular disease, SGLT2 inhibitors, and GLP-1 receptor agonists.

Evidence

This is a correction notice for the article identified by DOI 10.3389/fendo.2025.1605746.

Caveat

The abstract provides no corrected content, review findings, or diabetes and cardiovascular outcome details to summarize.

Simplified

Full Text

What this is

This document corrects omissions in the author affiliations of a previously published article.
The affiliations for David Alexander Vernaza Trujillo were not included in the original publication.
The erratum ensures proper attribution and acknowledgment of the author's institutional affiliations.

Essence

The erratum corrects the omission of author affiliations in a prior article regarding type 2 diabetes and cardiovascular disease.

Simplified

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients

3 days ago7 studies

Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study

1 week ago7 studies

Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients

2 weeks ago7 studies

Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group

3 weeks ago8 studies

New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients

4 weeks ago7 studies

GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery

5 weeks ago7 studies

Semaglutide linked to reduced cigarette craving in 24 smokers

6 weeks ago7 studies

Two-thirds of patients kept weight off after stopping GLP-1 drugs

7 weeks ago7 studies

Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months

9 weeks ago7 studies

Semaglutide linked to 2.5x higher risk of sudden vision loss

10 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief